Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Consensus Target Price from Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.80.

Several brokerages have commented on RGLS. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Hedge Funds Weigh In On Regulus Therapeutics

Large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 453,784 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 42,600 shares during the last quarter. Creative Planning purchased a new position in Regulus Therapeutics in the 3rd quarter worth $26,000. Rhumbline Advisers bought a new stake in Regulus Therapeutics in the second quarter worth $136,000. Finally, SG Americas Securities LLC purchased a new stake in Regulus Therapeutics during the third quarter valued at about $33,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Stock Performance

Shares of NASDAQ RGLS opened at $1.52 on Friday. The stock has a fifty day moving average of $1.53 and a 200-day moving average of $1.75. The stock has a market cap of $99.56 million, a PE ratio of -1.37 and a beta of 1.63. Regulus Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, sell-side analysts predict that Regulus Therapeutics will post -0.88 EPS for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.